Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Pancreas ; 46(2): 244-251, 2017 02.
Article in English | MEDLINE | ID: mdl-27861201

ABSTRACT

OBJECTIVES: Current pancreatic cancer diagnostics cannot reliably detect early disease or distinguish it from chronic pancreatitis. We test the hypothesis that optical spectroscopy can accurately differentiate cancer from chronic pancreatitis and normal pancreas. We developed and tested clinically compatible multimodal optical spectroscopy technology to measure reflectance and endogenous fluorescence from human pancreatic tissues. METHODS: Freshly excised pancreatic tissue specimens (39 normal, 34 chronic pancreatitis, 32 adenocarcinoma) from 18 patients were optically interrogated, with site-specific histopathology representing the criterion standard. A multinomial logistic model using principal component analysis and generalized estimating equations provided statistically rigorous tissue classification. RESULTS: Optical spectroscopy distinguished pancreatic cancer from normal pancreas and chronic pancreatitis (sensitivity, 91%; specificity, 82%; positive predictive value, 69%; negative predictive value, 95%; area under receiver operating characteristic curve, 0.89). Reflectance alone provided essentially the same classification accuracy as reflectance and fluorescence combined, suggesting that a rapid, low-cost, reduced-footprint, reflectance-based device could be deployed without notable loss of diagnostic power. CONCLUSIONS: Our novel, clinically compatible, label-free optical diagnostic technology accurately characterizes pancreatic tissues. These data provide the scientific foundation demonstrating that optical spectroscopy can potentially improve diagnosis of pancreatic cancer and chronic pancreatitis.


Subject(s)
Adenocarcinoma/diagnosis , Pancreatic Neoplasms/diagnosis , Pancreatitis, Chronic/diagnosis , Spectrum Analysis/methods , Diagnosis, Differential , Humans , Pancreas/pathology , Principal Component Analysis , ROC Curve , Reproducibility of Results , Spectrum Analysis/instrumentation
2.
Head Neck ; 36(1): 120-5, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23729173

ABSTRACT

BACKGROUND: The purpose of this study was to assess aspiration pneumonia (AsPn) rates and predictors after chemo-irradiation for head and neck cancer. METHODS: The was a prospective study of 72 patients with stage III to IV oropharyngeal cancer treated definitively with intensity-modulated radiotherapy (IMRT) concurrent with weekly carboplatin and paclitaxel. AsPn was recorded prospectively and dysphagia was evaluated longitudinally through 2 years posttherapy by observer-rated (Common Toxicity Criteria version [CTCAE]) scores, patient-reported scores, and videofluoroscopy. RESULTS: Sixteen patients (20%) developed AsPn. Predictive factors included T classification (p = .01), aspiration detected on videofluoroscopy (videofluoroscopy-asp; p = .0007), and patient-reported dysphagia (p = .02-.0003), but not observer-rated dysphagia (p = .4). Combining T classification, patient reported dysphagia, and videofluoroscopy-asp, provided the best predictive model. CONCLUSION: AsPn continues to be an under-reported consequence of chemo-irradiation for head and neck cancer. These data support using patient-reported dysphagia to identify high-risk patients requiring videofluoroscopy evaluation for preventive measures. Reducing videofluoroscopy-asp rates, by reducing swallowing structures radiation doses and by trials reducing treatment intensity in patients predicted to do well, are likely to reduce AsPn rates.


Subject(s)
Chemoradiotherapy/adverse effects , Deglutition Disorders/epidemiology , Oropharyngeal Neoplasms/therapy , Pneumonia, Aspiration/epidemiology , Adult , Aged , Biopsy, Needle , Chemoradiotherapy/methods , Cohort Studies , Deglutition Disorders/etiology , Deglutition Disorders/physiopathology , Female , Follow-Up Studies , Humans , Immunohistochemistry , Incidence , Longitudinal Studies , Male , Middle Aged , Multivariate Analysis , Observer Variation , Oropharyngeal Neoplasms/mortality , Oropharyngeal Neoplasms/pathology , Pneumonia, Aspiration/etiology , Pneumonia, Aspiration/physiopathology , Predictive Value of Tests , Prospective Studies , ROC Curve , Radiotherapy, Intensity-Modulated/adverse effects , Radiotherapy, Intensity-Modulated/methods , Risk Assessment , Survival Rate
3.
Transl Oncol ; 6(4): 442-6, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23908687

ABSTRACT

OBJECTIVES: The full potential of stereotactic body radiation therapy (SBRT), in the treatment of unresectable intrahepatic malignancies, has yet to be realized as our experience is still limited. Thus, we evaluated SBRT outcomes for primary and metastatic liver tumors, with the goal of identifying factors that may aid in optimization of therapy. METHODS: From 2005 to 2010, 62 patients with 106 primary and metastatic liver tumors were treated with SBRT to a median biologic effective dose (BED) of 100 Gy (42.6-180). The majority of patients received either three (47%) or five fractions (48%). Median gross tumor volume (GTV) was 8.8 cm(3) (0.2-222.4). RESULTS: With a median follow-up of 18 months (0.46-46.8), freedom from local progression (FFLP) was observed in 97 of 106 treated tumors, with 1- and 2-year FFLP rates of 93% and 82%. Median overall survival (OS) for all patients was 25.2 months, with 1- and 2-year OS of 81% and 52%. Neither BED nor GTV significantly predicted for FFLP. Local failure was associated with a higher risk of death [hazard ratio (HR) = 5.1, P = .0007]. One Child-Pugh Class B patient developed radiation-induced liver disease. There were no other significant toxicities. CONCLUSIONS: SBRT provides excellent local control for both primary and metastatic liver lesions with minimal toxicity. Future studies should focus on appropriate selection of patients and on careful assessment of liver function to maximize both the safety and efficacy of treatment.

4.
PLoS One ; 8(3): e57768, 2013.
Article in English | MEDLINE | ID: mdl-23469234

ABSTRACT

PURPOSE: There is little known about how brain white matter structures differ in their response to radiation, which may have implications for radiation-induced neurocognitive impairment. We used diffusion tensor imaging (DTI) to examine regional variation in white matter changes following chemoradiotherapy. METHODS: Fourteen patients receiving two or three weeks of whole-brain radiation therapy (RT) ± chemotherapy underwent DTI pre-RT, at end-RT, and one month post-RT. Three diffusion indices were measured: fractional anisotropy (FA), radial diffusivity (RD), and axial diffusivity (AD). We determined significant individual voxel changes of diffusion indices using tract-based spatial statistics, and mean changes of the indices within fourteen white matter structures of interest. RESULTS: Voxels of significant FA decreases and RD increases were seen in all structures (p<0.05), with the largest changes (20-50%) in the fornix, cingula, and corpus callosum. There were highly significant between-structure differences in pre-RT to end-RT mean FA changes (p<0.001). The inferior cingula had a mean FA decrease from pre-RT to end-RT significantly greater than 11 of the 13 other structures (p<0.00385). CONCLUSIONS: Brain white matter structures varied greatly in their response to chemoradiotherapy as measured by DTI changes. Changes in FA and RD related to white matter demyelination were prominent in the cingula and fornix, structures relevant to radiation-induced neurocognitive impairment. Future research should evaluate DTI as a predictive biomarker of brain chemoradiotherapy adverse effects.


Subject(s)
Brain Neoplasms/pathology , Corpus Callosum/pathology , Fornix, Brain/pathology , Gyrus Cinguli/pathology , Melanoma/pathology , Adult , Aged , Antineoplastic Agents/therapeutic use , Brain Neoplasms/therapy , Chemoradiotherapy , Cognition/drug effects , Cognition/radiation effects , Corpus Callosum/drug effects , Corpus Callosum/radiation effects , Demyelinating Diseases , Diffusion Tensor Imaging , Female , Fornix, Brain/drug effects , Fornix, Brain/radiation effects , Gamma Rays , Gyrus Cinguli/drug effects , Gyrus Cinguli/radiation effects , Humans , Male , Melanoma/therapy , Middle Aged , Nerve Fibers, Myelinated/drug effects , Nerve Fibers, Myelinated/pathology , Nerve Fibers, Myelinated/radiation effects , Prospective Studies
5.
Biometrics ; 68(2): 486-93, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21950470

ABSTRACT

Inference regarding the inclusion or exclusion of random effects in linear mixed models is challenging because the variance components are located on the boundary of their parameter space under the usual null hypothesis. As a result, the asymptotic null distribution of the Wald, score, and likelihood ratio tests will not have the typical χ(2) distribution. Although it has been proved that the correct asymptotic distribution is a mixture of χ(2) distributions, the appropriate mixture distribution is rather cumbersome and nonintuitive when the null and alternative hypotheses differ by more than one random effect. As alternatives, we present two permutation tests, one that is based on the best linear unbiased predictors and one that is based on the restricted likelihood ratio test statistic. Both methods involve weighted residuals, with the weights determined by the among- and within-subject variance components. The null permutation distributions of our statistics are computed by permuting the residuals both within and among subjects and are valid both asymptotically and in small samples. We examine the size and power of our tests via simulation under a variety of settings and apply our test to a published data set of chronic myelogenous leukemia patients.


Subject(s)
Biometry/methods , Linear Models , Adenosine Deaminase/blood , Biomarkers, Tumor/blood , Computer Simulation , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology , Likelihood Functions , Longitudinal Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...